Healing & RecoveryLimited ResearchResearch Only — Development HaltedC

ACE-031

Ramatercept / ActRIIB-Fc · Soluble activin receptor type IIB extracellular domain fused to IgG1-Fc acts as a ligand trap for myostatin (GDF-8), activins, and related ligands; removes myostatin’s brake on muscle satellite-cell activation and fiber hypertrophy; off-target BMP9 binding implicated in vascular adverse events

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts may use modeled aggregates when live snapshots are unavailable.

Studies cited
8
Research grade
C
Experience
76

Overall check-ins

Activity
43

Trackers & reports

Typical Dose

1–3 mg SubQ every 2–4 weeks in clinical trials — not an approved or recommended consumer dose

Route

Injectable (SubQ)

Cycle

Trial schedules used infrequent dosing; development halted — not recommended for repeated use

Storage

Lyophilized frozen; reconstituted refrigerated; minimize freeze-thaw

What is ACE-031?

ACE-031 (ramatercept) is a soluble ActRIIB-Fc fusion protein that traps myostatin and related TGF-β superfamily ligands to disinhibit muscle growth. Phase 1 healthy-volunteer data showed lean-mass and thigh-muscle volume increases, and Phase 2 work explored Duchenne muscular dystrophy — but clinical development was discontinued after bleeding-related adverse events (epistaxis, telangiectasias) linked to off-target BMP9 inhibition. Not FDA-approved; extreme caution.

Mechanism of Action

Soluble activin receptor type IIB extracellular domain fused to IgG1-Fc acts as a ligand trap for myostatin (GDF-8), activins, and related ligands; removes myostatin’s brake on muscle satellite-cell activation and fiber hypertrophy; off-target BMP9 binding implicated in vascular adverse events

Target: Myostatin (GDF-8), activins, and other ActRIIB ligands; BMP9 (off-target safety concern)

Research Indications

Tissue RepairMost Effective

Demonstrated acceleration of wound healing and soft tissue repair in research

Gut HealthEffective

Research shows beneficial effects on intestinal lining and GI function

Joint SupportEffective

Associated with reduced joint inflammation and improved mobility

Muscle RecoveryModerate

May support faster recovery from muscle strains and exercise stress

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Phase 1 Trial Context (healthy volunteers)0.02–3 mg/kg range studied; lean-mass signal at low-mg SubQSingle ascending dose / infrequentSubcutaneous injection
DMD Trial ContextProtocol-defined mg SubQ (development halted)Every 2–4 weeks in trial schedulesSubcutaneous injection
Evidence BoundaryNo approved or recommended consumer doseDo not self-titrate — development stopped for safetyQualified laboratory/professional protocol only

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Anticoagulants / antiplateletsAvoid
Follistatin-344 / other myostatin inhibitorsAvoid
NSAIDs (bleeding risk)Caution
IGF-1 LR3Caution
TB-500Monitor
BPC-157Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove ACE-031 vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.

Week 2–4

Improved tissue mobility and reduced discomfort. Early healing acceleration.

Week 4–8

Significant recovery milestones. Stronger tissue repair and functional improvement.

Week 8–12

Near-complete healing in many cases. Improved strength and tissue integrity.

Side Effects & Safety

  • Bleeding-related adverse events — notably epistaxis (nosebleeds) and telangiectasias — that halted clinical development
  • Vascular remodeling effects attributed to off-target BMP9 inhibition
  • Increased bleeding risk when combined with anticoagulants, antiplatelets, or NSAIDs
  • Injection site reactions (redness, bruising, discomfort)
  • Human safety is not established — development was discontinued for safety and there is no approved dose

FDA Status & Regulatory Info

Research Only — Development Halted

ACE-031 (ramatercept) is a soluble ActRIIB-Fc fusion protein that traps myostatin and related TGF-β superfamily ligands to disinhibit muscle growth. Phase 1 healthy-volunteer data showed lean-mass and thigh-muscle volume increases, and Phase 2 work explored Duchenne muscular dystrophy — but clinical development was discontinued after bleeding-related adverse events (epistaxis, telangiectasias) linked to off-target BMP9 inhibition. Not FDA-approved; extreme caution.

Rx Required: No
503A Ban: No
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 308 users report

Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.

308 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 62% · Mixed 22% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
-149
Recovery
-31
Digestive comfort
-151
Skin appearance
-99
Appetite control
-47

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
-53
Anxiety
-132
Flushing
-6
Headache
-103
GI discomfort
-48

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 100–200 mcg

Reports span 25–1000 mcg

25–50
4
50–100
14
100–200
18
200–400
9
400–600
6
600–1000
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing32stacking10side effects28ace-03116

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 30% more positive, and 12% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 68 repeat reporters

Share Your Experience

Rate ACE-031 in the PeptIQ app and help the community make informed decisions.

Research References (4)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers

    Attie KM, Borgstein NG, Yang Y, et al. Muscle Nerve. 2013

    Source
    Wiki study page →
  2. PubMed

    Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial

    Campbell C, McMillan HJ, Mah JK, et al. Muscle Nerve. 2017

    Source
    Wiki study page →
  3. PubMed

    Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies

    Baig MH, Ahmad K, Moon JS, et al. Front Physiol. 2022

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    ACE-031 (ActRIIB-Fc) studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for ACE-031.

Often tracked with

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your ACE-031 protocol in PeptIQ

Turn this ACE-031 guide into a living protocol — doses, vials, and history in one place.

Track ACE-031Open web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Half-Life
10-15 days
Target
Myostatin (GDF-8), activins, and other ActRIIB ligands; BMP9 (off-target safety concern)
Route
Injectable (SubQ)
Availability
Research only
Rx Required
No
503A Ban
No
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss ACE-031 with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for ACE-031.

Often tracked with